Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8395469 | 1.00 | HSD17B10 (0.71) | HSD17B10SMN1; SMN2RAB9AUCHL1NPC1 | |
| SCHEMBL9609459 | 1.00 | HSD17B10 (0.71) | HSD17B10SMN1; SMN2RAB9AUCHL1NPC1 | |
| SCHEMBL6926338 | 0.97 | HSD17B10 (0.67) | HSD17B10SMN1; SMN2RAB9AUCHL1NPC1 | |
| SCHEMBL6795956 | 0.95 | HSD17B10 (0.65) | HSD17B10SMN1; SMN2RAB9AUCHL1NPC1 | |
| SCHEMBL67044 | 0.94 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9AUCHL1NPC1 | |
| SCHEMBL27877016 | 0.94 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9AUCHL1NPC1 | |
| SCHEMBL67045 | 0.94 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9AUCHL1NPC1 | |
| SCHEMBL85536 | 0.94 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9AUCHL1NPC1 | |
| SCHEMBL6219872 | 0.94 | HSD17B10 (0.69) | HSD17B10SMN1; SMN2RAB9AUCHL1NPC1 | |
| SCHEMBL20492528 | 0.92 | HSD17B10 (0.68) | HSD17B10SMN1; SMN2RAB9AUCHL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112321475-B | Gamma-amino acid analogue and synthetic method thereof | 四川大学 | 2022-06-10 | — | — | CN | claimed |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4524154-A2 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2025-03-19 | — | — | EP | disclosed |
| EP-3848054-B1 | ANTIBODY-DRUG CONJUGATES OF CYCLIC DINUCLEOTIDE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2025-01-29 | — | — | EP | disclosed |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| CN-112714649-B | Cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2024-07-02 | — | — | CN | disclosed |
| CN-112321475-B | Gamma-amino acid analogue and synthetic method thereof | 四川大学 | 2022-06-10 | — | — | CN | disclosed |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| EP-3848054-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | Daiichi Sankyo Company, Limited (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-112714649-A | Novel cyclic dinucleotide derivatives and antibody drug conjugates thereof | 第一三共株式会社 | 2021-04-27 | — | — | CN | disclosed |
| US-8710008-B2 | Compounds, compositions and use | UNIVERSITETET I OSLO (NO) | 2014-04-29 | — | — | US | disclosed |
| US-20120245094-A1 | COMPOUNDS, COMPOSITIONS AND USE | UNIVERSITETET I OLSO (NO) | 2012-09-27 | — | — | US | disclosed |
| EP-2379589-A2 | COMPOUNDS, COMPOSITIONS AND USE | Universitetet I Oslo (NO) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010073009-A2 | COMPOUNDS, COMPOSITIONS AND USE | UNIVERSITETET I OSLO (NO) | 2010-07-01 | — | — | WO | disclosed |
| EP-0915908-A1 | DOLASTATIN PENTAPEPTIDE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-05-19 | — | — | EP | disclosed |
| US-5741892-A | Pentapeptides as antitumor agents | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-21 | — | — | US | disclosed |
| WO-1998004581-A1 | DOLASTATIN PENTAPEPTIDE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1998-02-05 | — | — | WO | disclosed |
| EP-0190852-A2 | Dipeptide derivatives and antihypertensive drugs containing them | AJINOMOTO CO., INC. (JP) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | HSD17B10 3888/4885SMN1; SMN2 3052/4885RAB9A 602/4885 |
| US-20120245094-A1 | COMPOUNDS, COMPOSITIONS AND USE | VIP, C9, NGLY1 | HSD17B10 1930/4885SMN1; SMN2 1620/4885RAB9A 3076/4885 |
| US-20220008549-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | HSD17B10 4004/4885SMN1; SMN2 3014/4885RAB9A 578/4885 |
| US-20240293567-A1 | NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF | STING1, CGAS, TLR9 | HSD17B10 4004/4885SMN1; SMN2 3014/4885RAB9A 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.